S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
S&P 500   5,069.53 (-0.38%)
DOW   39,069.23 (-0.16%)
QQQ   436.55 (-0.05%)
AAPL   181.16 (-0.75%)
MSFT   407.54 (-0.68%)
META   481.74 (-0.47%)
GOOGL   137.57 (-4.44%)
AMZN   174.73 (-0.15%)
TSLA   199.40 (+3.87%)
NVDA   790.92 (+0.35%)
NIO   5.65 (+4.63%)
AMD   176.01 (-0.29%)
BABA   76.51 (+0.72%)
T   16.59 (-1.25%)
F   11.95 (-1.57%)
MU   89.46 (+4.02%)
CGC   3.47 (+3.27%)
GE   154.77 (+0.94%)
DIS   107.69 (-0.05%)
AMC   4.45 (+0.23%)
PFE   27.18 (-2.09%)
PYPL   59.33 (+0.29%)
XOM   104.25 (+0.39%)
NASDAQ:GLYC

GlycoMimetics (GLYC) Stock Price, News & Analysis

$3.06
+0.16 (+5.52%)
(As of 02/26/2024 ET)
Today's Range
$2.84
$3.11
50-Day Range
$1.97
$3.49
52-Week Range
$1.11
$3.53
Volume
248,362 shs
Average Volume
370,581 shs
Market Capitalization
$197.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

GlycoMimetics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
226.8% Upside
$10.00 Price Target
Short Interest
Healthy
1.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.87mentions of GlycoMimetics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.60) to ($0.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.24 out of 5 stars

Medical Sector

167th out of 942 stocks

Pharmaceutical Preparations Industry

70th out of 425 stocks


GLYC stock logo

About GlycoMimetics Stock (NASDAQ:GLYC)

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GLYC Stock Price History

GLYC Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
GlycoMimetics, Inc. (GKO.F)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
GlycoMimetics' GMI-1687 Meets Primary Goal In Phase 1a Study
Promising Outlook for GlycoMimetics’ Uproleselan Drives Buy Rating
Q3 2023 GlycoMimetics Inc Earnings Call
GlycoMimetics: Q3 Earnings Snapshot
GlycoMimetics GAAP EPS of -$0.14 in-line
Earnings Outlook For GlycoMimetics
See More Headlines
Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2023
Today
2/26/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GLYC
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$12.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+242.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-46,690,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
$0.82 per share

Miscellaneous

Free Float
59,242,000
Market Cap
$188.02 million
Optionable
Optionable
Beta
2.23
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Harout Semerjian (Age 54)
    CEO, President & Director
    Comp: $1.1M
  • Ms. Rachel K. King (Age 65)
    Co-Founder & Director
    Comp: $226.43k
  • Mr. Brian M. Hahn (Age 50)
    Senior VP & CFO
    Comp: $748.27k
  • Ms. Stephanie R. Irish CPA (Age 53)
    Vice President of Accounting
  • Mr. Christian B. Dinneen-Long
    General Counsel & Company Secretary
  • Mr. Bruce Johnson (Age 56)
    Senior VP & Chief Commercial Officer
  • Dr. Edwin Rock M.D. (Age 63)
    Ph.D., Senior VP & Chief Medical Officer
  • Mr. Chinmaya Rath (Age 47)
    Senior VP & Chief Business Officer














GLYC Stock Analysis - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings
or view top-rated stocks.

What is GlycoMimetics' stock price target for 2024?

2 equities research analysts have issued 1-year price targets for GlycoMimetics' shares. Their GLYC share price targets range from $8.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 226.8% from the stock's current price.
View analysts price targets for GLYC
or view top-rated stocks among Wall Street analysts.

How have GLYC shares performed in 2024?

GlycoMimetics' stock was trading at $2.36 at the beginning of 2024. Since then, GLYC shares have increased by 29.7% and is now trading at $3.06.
View the best growth stocks for 2024 here
.

Are investors shorting GlycoMimetics?

GlycoMimetics saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 997,900 shares, an increase of 24.8% from the January 15th total of 799,700 shares. Based on an average daily trading volume, of 282,500 shares, the short-interest ratio is presently 3.5 days.
View GlycoMimetics' Short Interest
.

When is GlycoMimetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our GLYC earnings forecast
.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) announced its quarterly earnings results on Friday, November, 3rd. The biotechnology company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14). During the same quarter last year, the company posted ($0.16) EPS.

What other stocks do shareholders of GlycoMimetics own?
Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Goldman Sachs Group Inc. (1.43%), GSA Capital Partners LLP (0.31%), Bridgeway Capital Management LLC (0.31%), Northern Trust Corp (0.17%), MJP Associates Inc. ADV (0.16%) and Advisor OS LLC (0.16%). Insiders that own company stock include Brian M Hahn, Bruce S Johnson, Daniel M Junius, Edwin Rock, John L Magnani, Patricia S Andrews, Public Equities LP Invus and Scott D Sandell.
View institutional ownership trends
.

How do I buy shares of GlycoMimetics?

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLYC) was last updated on 2/26/2024 by MarketBeat.com Staff